middle.news
Why Did Argenica Therapeutics’ Losses Triple Despite R&D Grants?
8:28am on Wednesday 11th of February, 2026 AEDT
•
Healthcare
Read Story
Why Did Argenica Therapeutics’ Losses Triple Despite R&D Grants?
8:28am on Wednesday 11th of February, 2026 AEDT
Key Points
Loss after tax surged 221% to $3.82 million
Revenue fell 77% to $720,169 due to timing of R&D tax incentives
R&D expenses rose slightly to $3.03 million, focused on ARG-007 Phase 2 trial
Net operating cash outflows increased sharply to $5.5 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AGN
OPEN ARTICLE